Cas:1000802-33-4 N-(6-Iodobenzo[D][1,3]Dioxol-5-Yl)Acetamide manufacturer & supplier

Chemical Name:N-(6-Iodobenzo[D][1,3]Dioxol-5-Yl)Acetamide

CAS.NO:1000802-33-4

Synonyms:N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide

Molecular Formula:C₉H₈INO₃

Molecular Weight:305.06900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:47.56000

Exact Mass:304.95500

LogP:2.05130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide Use and application,N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide technical grade,usp/ep/jp grade.

Related News: The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. N-(6-Iodobenzo[D][1,3]Dioxol-5-Yl)Acetamide manufacturer A number of UK citizens who failed to leave the coronavirus-struck Chinese city of Wuhan last week are now on a second flight to Europe, UK Foreign Secretary Dominic Raab said Sunday. N-(6-Iodobenzo[D][1,3]Dioxol-5-Yl)Acetamide supplier Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. N-(6-Iodobenzo[D][1,3]Dioxol-5-Yl)Acetamide vendor Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. N-(6-Iodobenzo[D][1,3]Dioxol-5-Yl)Acetamide factory Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.